PMID- 17240618
OWN - NLM
STAT- MEDLINE
DCOM- 20070208
LR  - 20191110
IS  - 1541-2555 (Print)
IS  - 1541-2563 (Linking)
VI  - 3
IP  - 3
DP  - 2006 Aug
TI  - Clinical safety of long-acting beta2-agonist and inhaled corticosteroid 
      combination therapy in COPD.
PG  - 163-71
AB  - Long-acting beta2-agonist (LABA) and inhaled corticosteroid (ICS) combination 
      therapy is recommended by international treatment guidelines for COPD. The 
      current literature concerning the safety of LABAs and ICS, both as monotherapies 
      and in combination, in patients with COPD is reviewed. Bronchodilators such as 
      LABAs are key treatments for COPD due to their effects on bronchial smooth muscle 
      and airflow limitation. LABAs are well-tolerated in patients with COPD, with a 
      low incidence of reported adverse events (AEs). Most AEs associated with LABA use 
      are due to systemic exposure and include muscle tremor and cardiac effects. 
      Placebo-controlled studies in patients with COPD demonstrate that there is no 
      increase in risk of cardiac AEs with LABA therapy. ICS therapy targets airway 
      inflammation in COPD, and is associated with a reduction in the frequency of COPD 
      exacerbations, and improvements in symptoms, lung function and health status. 
      Localized effects such as oropharyngeal irritation are common with ICS, but are 
      not considered to be serious. Potential ocular effects with ICS therapy in 
      patients with COPD have been identified and require further investigation. Rare, 
      but more serious AEs related to ICS use are the effects on bone and the 
      suppression of endogenous cortisol production; however, the clinical relevance of 
      these effects is unclear. Clinical data indicate that LABA/ICS combination 
      therapy is more effective in COPD than either agent used alone and is not 
      associated with any additional AEs.
FAU - Decramer, Marc
AU  - Decramer M
AD  - Respiratory Division University Hospital, Katholieke Universiteit Leuven, Leuven, 
      Belgium. marc.decramer@uz.kuleuven.be
FAU - Ferguson, Gary
AU  - Ferguson G
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - COPD
JT  - COPD
JID - 101211769
RN  - 0 (Adrenergic beta-Agonists)
RN  - 0 (Bronchodilator Agents)
RN  - 0 (Ethanolamines)
RN  - 0 (Glucocorticoids)
RN  - 51333-22-3 (Budesonide)
RN  - 6EW8Q962A5 (Salmeterol Xinafoate)
RN  - QF8SVZ843E (Albuterol)
RN  - W34SHF8J2K (Formoterol Fumarate)
SB  - IM
MH  - Administration, Inhalation
MH  - Adrenergic beta-Agonists/pharmacology/*therapeutic use
MH  - Albuterol/analogs & derivatives/pharmacology/therapeutic use
MH  - Bronchodilator Agents/therapeutic use
MH  - Budesonide/administration & dosage/therapeutic use
MH  - Drug Therapy, Combination
MH  - Ethanolamines/pharmacology
MH  - Formoterol Fumarate
MH  - Glucocorticoids/administration & dosage/*therapeutic use
MH  - Heart Rate/drug effects
MH  - Humans
MH  - Pulmonary Disease, Chronic Obstructive/*drug therapy
MH  - Randomized Controlled Trials as Topic
MH  - Salmeterol Xinafoate
MH  - Treatment Outcome
RF  - 68
EDAT- 2007/01/24 09:00
MHDA- 2007/02/09 09:00
CRDT- 2007/01/24 09:00
PHST- 2007/01/24 09:00 [pubmed]
PHST- 2007/02/09 09:00 [medline]
PHST- 2007/01/24 09:00 [entrez]
AID - 10.1080/15412550600830263 [doi]
PST - ppublish
SO  - COPD. 2006 Aug;3(3):163-71. doi: 10.1080/15412550600830263.